OncoMed Pharmaceuticals Inc. said Thursday that the U.S. Food and Drug Administration has accepted an Investigational New Drug filing for its cancer drug.
Redwood City-based OncoMed said it can now begin Phase I clinical testing of OMP-18R5, triggering a $20 million milestone payment from Bayer to OncoMed.
No comments:
Post a Comment